LP002 + carboplatin + etoposide

LP002 + carboplatin + etoposide is a combination therapy under investigation for the treatment of cancer, specifically in perioperative settings for resectable, PD-L1 positive gastric or gastroesophageal junction (GEJ) cancer. **LP002** is a humanized monoclonal antibody targeting **programmed death ligand-1 (PD-L1)**, thereby blocking its interaction with PD-1 and B7.1 on T cells, which releases immune inhibition and enhances antitumor immune activity. **Carboplatin** is a cytotoxic platinum complex that acts by generating DNA crosslinks, leading to apoptosis of rapidly dividing cells. **Etoposide** is a small molecule that inhibits **topoisomerase II**, preventing DNA religation and inducing cell cycle arrest during the S/G2 phase. This combination is administered intravenously and has shown promising efficacy and manageable safety profiles in phase 1 trials for locally advanced, resectable gastric and GEJ cancers[1][3][7].